Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/filamentous-fungi-pathway-balancing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Filamentous Fungi Pathway BalancingFilamentous Fungi Pathway Balancing Patents: Who Holds the Claim Space
- Concentrated at the top. The five leading assignees hold 74.8% of all 103 records in scope, and the ten leading assignees hold 99.0% — almost nothing sits outside that group.
- Filings have cooled from a 2022 peak. Publications ran 2017's 3 up to a peak of 9 in 2022, then fell to 0 by 2024 (2021→2024: -100%), though the most recent years are still filling in as publication lags filing by about 18 months.
- Enzymatic and analytical claims dominate. C12P fermentation/enzymatic synthesis (67.0%) and C12Q measuring/testing (58.3%) sit well above food, baking and brewing-specific classes, showing the claim pressure is on core pathway mechanics, not end-use formats.
103
Published Records
75%
Top-5 Share of All Records
-100%
Filing Growth 2021→2024
EP
Leading Jurisdiction
Filing growth compares 2021 (1 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 103 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This dataset tracks patent filings at the intersection of filamentous fungal host engineering and metabolic flux control — claims that address enzyme ratios, precursor supply, byproduct suppression, and pathway bottlenecks inside recombinant fungal systems. The search combines fungal-host terminology with flux-and-bottleneck language under the core genetic engineering and enzyme/DNA testing classification codes, so it captures engineering claims rather than general fungal biology or unrelated fermentation equipment.
Coverage runs from 2015 through the 2026-07-31 data cut-off, spanning 103 published records. The scope is narrow by design: it isolates work on balancing metabolic flux inside a fungal chassis, rather than the broader universe of industrial fermentation or general genetic engineering.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Data
Filing trends and technology composition
Two views of the same 103 records: how filings moved year over year, and which IPC subclasses carry the claim volume.
Filing trend, 2017-2026
Publications rose from 3 in 2017 to a peak of 9 in 2022, then declined to 0 by 2024 — a -100% move over that three-year span. Because publication typically lags filing by roughly 18 months, the 2025-2026 tail understates real activity and should not be read as a slowdown on its own.
Technology composition by IPC subclass
Every record in scope carries a C12N classification by construction. Beyond that base, C12P fermentation and enzymatic synthesis claims (67.0% of 103 records) and C12Q measuring/testing claims (58.3%) are the dominant overlays, well ahead of medicinal (A61K, 23.3%), sugars/nucleic acids (C07H, 21.4%), food (A23L, 20.4%), baking (A21D, 15.5%) and brewing (C12C, 15.5%). Because records can carry multiple classes, these shares sum to more than 100% of the record total.
Shares are the percentage of the 103 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Filamentous Fungi Pathway Balancing with Eureka
This page is one run against one query. Ask Eureka your own question about filamentous fungi pathway balancing and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Most-cited records and a representative filing
Representative filing
Pentose Fermentation By a Recombinant Microorganism (US20110294170A1)
CODEXIS, INC.
The present invention provides recombinant nucleic acid constructs comprising a xylose isomerase polynucleotide, a recombinant fungal host cell comprising a recombinant xylose isomerase polynucleotide, and related methods.Filed by Codexis; anchors a family of pentose-fermentation claims that recur among the most-cited records in this set.
Most-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20070157329A1 | Amylases, nucleic acids encoding them and methods for making and using them | 42 |
| 2 | US20130288325A1 | Biofuel and chemical production by recombinant microorganisms via fermentation of proteinaceous biomass | 32 |
| 3 | US20080286844A1 | Metabolically Engineered Cells for the Production of Resveratrol or an Oligomeric or Glycosidically-Bound Der… | 21 |
| 4 | US20130004998A1 | Pentose fermentation by a recombinant microorganism | 15 |
| 5 | US20110294170A1 | Pentose Fermentation By a Recombinant Microorganism | 12 |
| 6 | US9284566B2 | Biofuel and chemical production by recombinant microorganisms via fermentation of proteinaceous biomass | 11 |
| 7 | WO2012013197A2 | Aspergillus encoding beta-glucosidases and nucleic acids encoding same | 11 |
| 8 | WO2010034686A1 | Improved statin production | 10 |
| 9 | US20110223640A1 | Improved statin production | 7 |
| 10 | WO2004074490A2 | Method for transforming blakeslea strains | 5 |
Citation counts reflect influence within this searched corpus and favour older filings; treat them as a signal of prior-art density, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Three findings that shape where a new filing would actually land in this landscape.
Concentration
74.8% of 103 records
top 5 assignees combined
The field is a five-player game with a thin tail beyond it
Five assignees hold three-quarters of all records in scope, and the top ten account for 99.0% of the field. A newcomer is not entering an open market — it is entering the gaps between a small number of dense filers.
Source: assignee ranking, 66 companies
Momentum
9 filings in 2022 (peak)
then 0 by 2024
Publication activity has cooled from its peak, but the tail is unreliable
The -100% move from 2021 to 2024 is real in the published record, but the 18-month lag between filing and publication means 2025-2026 figures are still incomplete. Read the recent flat line as a data artefact, not a settled market signal.
Source: filing trend, 2017-2026
Claim pressure
67.0% C12P / 58.3% C12Q
of 103 records
Core enzymatic and measurement claims outweigh end-use formats
Fermentation/enzymatic-synthesis and measuring/testing classifications dominate over food, baking and brewing overlays. The pressure sits on pathway mechanics and flux measurement methods themselves, which is where a new entrant should expect the densest prior art.
Source: IPC composition, 103 records
Collaboration
10 co-assignee pairs
strongest pair: 12 shared records
A handful of assignee pairs co-file repeatedly
The strongest co-assignee link accounts for 12 shared records, with two further pairs at 6 each. These recurring pairings suggest licensing or joint-development relationships rather than incidental overlap.
Source: co-assignee pairs
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to filamentous fungi pathway balancing, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds the ground, and where the gaps are
The ranked leaders concentrate almost all activity in this field, but the specific sub-areas they have not claimed are where a new filing has room to stand.
Leader
38 records
single largest assignee
One filer sits well ahead of the field
The leading assignee holds 38 of the 103 records in scope, more than six times the count at fifth place (6). That gap defines the shape of the whole landscape: one dominant filer, a mid-tier of a handful of active companies, then a long tail.
Source: assignee ranking
Mid-tier
6 records at 5th, 4 at 10th
drop-off past the leader
A compact group of active filers below the leader
Filings drop sharply after the leader but stay active down to tenth place, which still holds 4 records. This mid-tier is where most of the collaborative co-assignee activity in the dataset originates.
Source: assignee ranking
Momentum
0 in latest year
for every top co-filer
Recent-year activity has gone quiet across the named leaders
Every one of the top co-assignee pairs shows zero filings in the latest year of this dataset. Given the publication lag, this is more likely an artefact of the data cut-off than evidence these companies have exited the field.
Source: recent-year momentum by assignee
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| BASF Enzymes LLC | 0 | — |
| Syngenta Participations AG | 0 | — |
| Verenium Corp | 0 | — |
| DSM IP Assets B.V. | 0 | — |
| BASF SE | 0 | — |
| Evolva SA | 0 | — |
| Danisco US Inc. | 0 | -100% |
| Diversa Corporation | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to a concentrated field with specific open branches. These are reasonable next steps for a team deciding where to file or partner.
Map the leader's claim boundaries precisely
With one assignee holding 38 of 103 records, understanding exactly which claim language it uses in the enzymatic and measurement classes is the first filter for any new filing.
Explore assignee claim scope in EurekaTest the under-claimed branches against fresh prior art
The baking, brewing and food-grade sub-areas show filing activity well below the core classes. A targeted search of recent applications there would confirm whether the gap still holds.
Run a white-space search in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
The field is heavily concentrated: the five leading assignees together hold 74.8% of the 103 records in scope, and the ten leading assignees hold 99.0%. One assignee alone accounts for 38 records, well ahead of the company in fifth place at 6. This means most of the useful competitive intelligence in this space comes from watching a small group of companies rather than tracking a broad field of independent filers.
Published filings rose from 3 in 2017 to a peak of 9 in 2022, then fell to 0 by 2024, a -100% move over that three-year span. However, patent publication typically lags the actual filing date by around 18 months, so the 2025-2026 figures in any dataset are still incomplete and should not be read as proof the field has gone quiet. The safest reading is that activity peaked around 2022 and the true 2024-2026 trend will only be clear once later publications catch up.
Every record in this dataset carries a core genetic-engineering classification (C12N), but the largest overlays are fermentation and enzymatic synthesis (C12P, 67.0% of records) and enzyme/DNA measuring and testing methods (C12Q, 58.3%). Smaller but notable shares appear in medicinal preparations, sugars and nucleic acids, food, baking and brewing applications. Because a single filing can carry several classifications, these percentages add up to more than 100% of the record total.
US20110294170A1 covers recombinant nucleic acid constructs built around a xylose isomerase polynucleotide and a recombinant fungal host cell carrying that construct, filed by Codexis. Anyone building a xylose-isomerase-based pentose fermentation route in a fungal chassis needs to check this claim family closely, since it is among the most-cited records in this dataset and sits at the center of several related filings. Designing around it typically means using a different pentose-conversion enzyme class or a materially different construct architecture rather than a minor sequence variation.
The under-claimed branches sit in application-specific overlays rather than the core mechanics: baking-specific enzyme ratio control, brewing byproduct suppression, and food-grade fungal host optimisation all show materially lower filing shares than the core fermentation and measurement classes. These branches still see enough activity to confirm commercial interest, but not enough to suggest the claim space is fully occupied. A first filing there would likely combine a food- or beverage-specific process step with a flux-control claim already established in the core classes.
Answers are grounded in the same dataset. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Filamentous Fungi Pathway Balancing in depth with Eureka
Go past this page: query the whole filamentous fungi pathway balancing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.